SOHO state-of-the-art update and next questions: MPN

The discovery of the activating JAK2V617F mutation in 2005 in the majority of patients with the classic Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) spurred intense interest in research into these disorders, culminating in the identification of activating mutations in MPL in 2006 and indels in CALR in 2013, thus providing additional mechanistic explanations for the universal activation of Janus kinase-signal transducer and activator of transcription (JAK-STAT) observed in these conditions, and the success of the JAK1/2 inhibitor ruxolitinib, which first received regulatory approval in 2011.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Article Source Type: research

Related Links:

Publication date: Available online 28 June 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Aaron Gerds, Derrick Su, Anastasia Martynova, Benjamin Pannell, Sudipto Mukherrjee, Caitlin O’Neill, Mikkael Sekeres, Casey O’ConnellAbstractMyelofibrosis (MF) is one of the classic myeloproliferative neoplasms (MPNs) and can occur de novo or following transformation from polycythemia vera (PPV MF) or essential thrombocythemia (PET MF). It can be associated with constitutional symptoms and splenomegaly, both of which can greatly affect quality of life. The only curative option for MF is allogeneic stem cell t...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionThese data confirm that many patients with PV experience symptoms, QoL impairments, and work productivity impairments that negatively affect their lives. Longitudinal data from REVEAL will be important for evaluating how PROs change over time in these patients.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 28 June 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Aaron Gerds, Derrick Su, Anastasia Martynova, Benjamin Pannell, Sudipto Mukherrjee, Caitlin O’Neill, Mikkael Sekeres, Casey O’ConnellAbstractMyelofibrosis (MF) is one of the classic myeloproliferative neoplasms (MPNs) and can occur de novo or following transformation from polycythemia vera (PPV MF) or essential thrombocythemia (PET MF). It can be associated with constitutional symptoms and splenomegaly, both of which can greatly affect quality of life. The only curative option for MF is allogeneic stem cell t...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionThese data confirm that many patients with PV experience symptoms, QoL impairments, and work productivity impairments that negatively affect their lives. Longitudinal data from REVEAL will be important for evaluating how PROs change over time in these patients.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Myelofibrosis (MF) is one of the classic myeloproliferative neoplasms (MPNs) and can occur de novo or following transformation from polycythemia vera (PPV MF) or essential thrombocythemia (PET MF). It can be associated with constitutional symptoms and splenomegaly, both of which can greatly affect quality of life. The only curative option for MF is allogeneic stem cell transplantation. Studies have shown JAK2 inhibitors such as ruxolitinib are effective in reducing both splenomegaly and symptom burden.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
This article is protected by copyright. All rights reserved.
Source: American Journal of Hematology - Category: Hematology Authors: Tags: Research Article Source Type: research
Publication date: Available online 2 December 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Prithviraj Bose, Jason Gotlib, Claire N. Harrison, Srdan Verstovsek The discovery of the activating JAK2 V617F mutation in 2005 in the majority of patients with the classic Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) spurred intense interest in research into these disorders, culminating in the identification of activating mutations in MPL in 2006 and indels in CALR in 2013, thus providing additional mechanistic explanations for the universal activation of Janus kinase-signal transducer and ac...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Racial and ethnic disparities in patients with solid malignancies have been well documented. Less is known about these disparities in patients with hematologic malignancies. With the advent of novel chemotherapeutics and targeted molecular, cellular, and immunologic therapies, it is important to identify differences in care that may lead to disparate outcomes. This review provides a critical appraisal of the empirical research on racial and ethnic disparities in incidence, survival, and outcomes in patients with hematologic malignancies. The review focuses on patients with acute myeloid leukemia, acute lymphocytic leukemia...
Source: Blood - Category: Hematology Authors: Tags: Myeloid Neoplasia, Lymphoid Neoplasia, Review Articles, Clinical Trials and Observations Source Type: research
Patients with accelerated phase (AP) myelofibrosis (MF;>10% blasts in bone marrow [BM] or peripheral blood [PB]) have shorter overall survival (OS) than those in the chronic phase (
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Myeloproliferative Neoplasms Source Type: research
Clinical, cytogenetic, and gene-based studies have been used to inform biology and improve prognostication for patients with acute myeloid leukemia (AML), myelodysplasia (MDS), and myeloproliferative neoplasms (MPN). Most recently, a series of candidate gene and whole genome studies have identified recurrent somatic mutations in AML patients including TET2, ASXL1, DNMT3A, and cohesin complex mutations. Moreover, these mutations can be used to improve risk stratification in AML independent of established clinical parameters.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
More News: Hematology | Leukemia | Lymphoma | Myeloma | Myeloproliferative Disorders